Hehn Sean T, Miller Thomas P
Department of Medicine, Arizona Cancer Center at the University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA.
Curr Hematol Rep. 2004 Jan;3(1):17-26.
The combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the most commonly used chemotherapy regimen in North America for the treatment of advanced-stage Hodgkin's lymphoma. Although 60% to 70% of patients with stages III and IV Hodgkin's lymphoma may be cured with ABVD, many patients relapse or progress despite standard therapy. Two new regimens, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone), have shown short-term (3-5 years) overall survival results of 90% or better. Although the results of pilot studies using these regimens and one randomized trial with BEACOPP look promising, the toxicities are substantial. To evaluate overall benefit, two large intergroup trials are underway comparing ABVD versus BEACOPP (European Organization for Research and Treatment of Cancer 20012) and ABVD versus Stanford V (E2496) in advanced Hodgkin's lymphoma.
阿霉素、博来霉素、长春花碱和达卡巴嗪联合方案（ABVD）是北美治疗晚期霍奇金淋巴瘤最常用的化疗方案。尽管Ⅲ期和Ⅳ期霍奇金淋巴瘤患者中有60%至70%可能通过ABVD治愈，但许多患者尽管接受了标准治疗仍会复发或病情进展。两种新方案，即博莱霉素、依托泊苷、阿霉素、环磷酰胺、长春新碱、丙卡巴肼和泼尼松联合方案（BEACOPP）以及斯坦福V方案（长春花碱、阿霉素、长春新碱、博来霉素、氮芥、依托泊苷和泼尼松），已显示出短期（3至5年）总生存率达90%或更高的结果。尽管使用这些方案的初步研究结果以及一项BEACOPP随机试验看起来很有前景，但毒性很大。为评估总体获益情况，两项大型组间试验正在进行，比较晚期霍奇金淋巴瘤中ABVD与BEACOPP（欧洲癌症研究与治疗组织20012）以及ABVD与斯坦福V方案（E2496）。
